By THE ASSOCIATED PRESSAPRIL 14, 2015
First-quarter profit for Johnson & Johnson, the world’s biggest maker of health care products, uncharacteristically fell 8.6 percent, to $4.32 billion, hurt by sharply unfavorable exchange rates, a major divestiture and competition to its new hepatitis C drug. The results surpassed Wall Street expectations, but the company reduced its full-year profit forecast, saying it now expects earnings of $6.04 to $6.19 a share, down from $6.12 to $6.27.A version of this brief appears in print on April 15, 2015, on Page B2 of the New York edition with the headline: First-Quarter Profit Falls at Johnson & Johnson.  Order Reprints| Today's Paper|Subscribe

We’re interested in your feedback on this page. Tell us what you think.